New York’s Wadsworth Center Newborn Screening Program is First in the United States to Implement Screening for Metachromatic Leukodystrophy (MLD)
The New York State Newborn Screening Program at the Wadsworth Center has become the first program in the United States to implement universal newborn screening for Metachromatic Leukodystrophy (MLD), a devastating but now treatable lysosomal storage disorder. MLD is caused by low or absent activity of the arylsulfatase A (ARSA) enzyme, leading to toxic accumulation of sulfatides and progressive damage to the nervous system.
READ MORE about New York’s Wadsworth Center Newborn Screening Program is First in the United States to Implement Screening for Metachromatic Leukodystrophy (MLD)